Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Russell's viper phospholipase A2 (vvPLA2) is a small, secreted, calcium-dependent enzyme (13–18 kDa) found in the venom of Daboia russelii (Russell’s viper). It belongs to the group IIA secreted phospholipase A2 family and is stabilized by 6–7 disulfide bonds[1][2][3]. Structurally, the enzyme features an N-terminal alpha helix, two disulfide-connected alpha helices (housing the catalytic dyad His48/Asp49), a double-stranded antiparallel beta-sheet, a calcium-binding loop, and a flexible C-terminal loop[1][2][3]. vvPLA2 hydrolyzes the sn-2 acyl bond of membrane phospholipids, releasing fatty acids and lysophospholipids, thereby disrupting cell membranes. Variants of this enzyme (acidic and basic isoforms) display differences in toxicity, with basic forms being more toxic due to higher affinity for cellular membranes[2]. This enzyme contributes to a range of toxic manifestations in envenomation, including hemostatic disturbances, cytotoxicity, neuromuscular impairment, and inflammation. There is active interest in developing antivenoms and small-molecule inhibitors to neutralize PLA2-mediated toxicity, though structural diversity poses notable therapeutic challenges[1][2].
Hydrolysis of sn-2 position in phospholipids, leading to production of lysophospholipids and fatty acids, which disrupts cellular membranes and induces cytotoxicity[1][2][3]. Calcium-dependent enzyme catalysis requiring a cofactor and a conserved catalytic dyad (His48/Asp49)[1][2][3]. Some basic vvPLA2s act through direct cytolytic, anticoagulant, or neurotoxic mechanisms[2][4].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Russell's viper phospholipase A2 (vvPLA2).